Commercial Accelerator Scheme
Providing a cash injection for early stage inventions and services
The Commercial Accelerator Scheme (CAS) funds the development of innovations at all stages of the commercial pipeline to the point where they can be commercialised as new products, services and companies.
Through CAS, the University contributes up to $400,000 each year in cash to research projects with a commercial application. The funding is provided for proof of concept and early commercialisation activities, to promote translational research for impact, and greater industry engagement.
University of Adelaide Enterprise celebrated our commercialisation ready researchers on December 19th 2016 where we announced the outstanding recipients of the 2016 University of Adelaide Commercial Accelerator Scheme (CAS). The recipients were:
- Professor Mark Nottle
- Professor Rob McLaughlin
- A/Professor Martin O'Connor
- Dr Erik Schartner
- Professor John Beltrame
Here are just a couple of our successful Award Recipients, Professor Rob McLaughlin and Dr Erik Schartner:
Image Source: The Adelaide Advertiser
Applications closed 7 October 2016.
For more information email email@example.com
- Successful Applications 2015
- Commercial development of a novel intraceullular based vaccine for the prevention of Apicomlexan parasitic diseases and other intracellular pathogens – led by Dr Ryan O’Handley
- A novel Parkinson’s disease therapy using AstraZeneca’s Saracatinib (AZD0530) to inhibit Fyn kinase – led by Dr Lyndsey Collins-Praino
- Mucositis therapy with AstraZeneca’s AZD1236 – led by Associate Professor Rachel Gibson
- Spin out, CarbOzide Pty Ltd – led by Professor Vincent Bulone
- Next-generation photonic magnetic sensing for geophysical exploration – led by Professor Andre Luiten
- A new formulation of embryo production media for cattle in vitro embryo production – led by Associate Professor Jeremy Thompson